Literature DB >> 17452901

Rapamycin enhances the number of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro.

Elena Uss1, Si-La Yong, Berend Hooibrink, Rene A W van Lier, Ineke J M ten Berge.   

Abstract

BACKGROUND: Regulatory T cells (T(reg) cells) may be operational in both the induction and maintenance of transplantation tolerance. We recently showed that alloantigen-induced CD103+ CD8+ T cells strongly suppressed T-cell proliferation in mixed lymphocyte culture (MLC) via a contact-dependent mechanism. CD103 directs T lymphocytes to their ligand E-cadherin, which is expressed on renal tubular epithelial cells, and CD103+ CD8+ T cells have been described to be present in late renal allograft rejection.
METHODS: We studied the influence of prednisolone, cyclosporin, tacrolimus, CD25 monoclonal antibodies, rapamycin, and mycophenolate mofetil (MMF) on the development and functional activity of alloantigen-activated CD103+ CD8+ T cells in MLC.
RESULTS: Calcineurin inhibitors, MMF, and CD25mAb did not influence the number of CD103 expressing CD8+ T cells. In contrast, corticosteroids diminished CD103 expression on alloactivated CD8+ T cells, which appeared to be caused by their inhibitory action on myeloid dendritic cells. Addition of rapamycin to allocultures led to an increased percentage of CD103+ CD8+ alloreactive T cells. Moreover, in the presence of rapamycin, these cells tended to show higher suppressive capacity.
CONCLUSIONS: Alloreactive CD103+ CD8+ T(reg) cells may expand and exert their suppressive function during immunosuppressive treatment with rapamycin. These data are relevant in the design of immunosuppressive drug regimens intended to induce and/or maintain transplantation tolerance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17452901     DOI: 10.1097/01.tp.0000259555.29762.f0

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.

Authors:  Teresa Caballero-Velázquez; Luis Ignacio Sánchez-Abarca; Silvia Gutierrez-Cosio; Belén Blanco; Cristina Calderon; Carmen Herrero; Soraya Carrancio; Concepción Serrano; Consuelo del Cañizo; Jesús F San Miguel; José A Pérez-Simón
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

2.  Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).

Authors:  Craig L Slingluff; Gina R Petroni; Kerrington R Molhoek; David L Brautigan; Kimberly A Chianese-Bullock; Amber L Shada; Mark E Smolkin; Walter C Olson; Alison Gaucher; Cheryl Murphy Chase; William W Grosh; Geoffrey R Weiss; Aubrey G Wagenseller; Anthony J Olszanski; Lainie Martin; Sofia M Shea; Gulsun Erdag; Prahlad Ram; Jeffrey E Gershenwald; Michael J Weber
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

Review 3.  Advances on Non-CD4 + Foxp3+ T Regulatory Cells: CD8+, Type 1, and Double Negative T Regulatory Cells in Organ Transplantation.

Authors:  Ann J Ligocki; Jerry Y Niederkorn
Journal:  Transplantation       Date:  2015-08       Impact factor: 4.939

4.  The pyrimidin analogue cyclopentenyl cytosine induces alloantigen-specific non-responsiveness of human T lymphocytes.

Authors:  N Nikolaeva; F J Bemelman; S-L Yong; A Verschuur; R A W van Lier; I J M ten Berge
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

Review 5.  Treating autoimmune disease by targeting CD8(+) T suppressor cells.

Authors:  Christine Konya; Jorg J Goronzy; Cornelia M Weyand
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388

6.  T regulatory cells: an overview and intervention techniques to modulate allergy outcome.

Authors:  Subhadra Nandakumar; Christopher Wt Miller; Uday Kumaraguru
Journal:  Clin Mol Allergy       Date:  2009-03-12

7.  Role of CD8(+) regulatory T cells in organ transplantation.

Authors:  Jiyan Su; Qingfeng Xie; Yang Xu; Xian C Li; Zhenhua Dai
Journal:  Burns Trauma       Date:  2014-01-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.